Prognostic Factors and Survival Outcomes of Surgical Resection of Huge Hepatocellular Carcinomas.
Hepatocellular carcinoma
Huge
Liver resection
Prognostic factors
Survival outcomes
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
6
5
2019
medline:
4
11
2020
entrez:
5
5
2019
Statut:
ppublish
Résumé
The aim of the study was to analyze the various prognostic factors that influence survival and clinical outcomes in patients undergoing liver resection for huge hepatocellular carcinomas. The records of patients who underwent curative surgery between 1991 and 2011 for huge hepatocellular carcinoma were analyzed. Various prognostic factors that influenced the survival were studied. The patients were followed up till November 2016. The number of patients who underwent liver resection with huge hepatocellular carcinoma during the study period was 17; this included 14 males and 3 females. The median age of the study population was 52 years. The median serum AFP in the study population was 132.3 ng/ml (range 2 to 187,000 ng/ml). 41.2% of the patients were hepatitis B positive. The overall morbidity was 6%. The mortality rate was nil. The mean size of the resected specimen was 13.9 cm ± 3.6 cm. The overall recurrence rate was 76.5%. The local recurrence rate was 29.4%. The median time to recurrence was 8 months. The 5-year disease-free survival and overall survival of the study group were 26% and 32%, respectively. The factors that predicted an adverse survival outcome after the log-rank test for univariate analysis using life-table method were presence of lymphovascular invasion (p = 0.047), age ≤ 55 years (p = 0.021), and raised serum AFP (p = 0.041). The factors that predict an adverse outcome after surgery in patients with huge hepatocellular carcinomas were the presence of lymphovascular invasion, raised serum AFP, and age ≤ 55 years.
Identifiants
pubmed: 31054105
doi: 10.1007/s12029-019-00240-x
pii: 10.1007/s12029-019-00240-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-253Références
J Surg Res. 2012 Dec;178(2):743-50
pubmed: 22656039
Hepatology. 2001 Jun;33(6):1394-403
pubmed: 11391528
World J Surg. 2013 Feb;37(2):452-8
pubmed: 23188527
J Surg Oncol. 2016 May;113(6):621-7
pubmed: 26861568
J Surg Oncol. 2000 Feb;73(2):109-14
pubmed: 10694648
J Am Coll Surg. 1999 Mar;188(3):304-9
pubmed: 10065820
J Am Coll Surg. 2002 May;194(5):592-602
pubmed: 12022599
World J Surg. 2015 Oct;39(10):2519-28
pubmed: 26126423
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Cancer. 1994 Nov 15;74(10):2772-80
pubmed: 7954236
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Br J Surg. 1998 Dec;85(12):1654-7
pubmed: 9876069
Ann Surg Oncol. 2007 Oct;14(10):2817-23
pubmed: 17690940
Aliment Pharmacol Ther. 2006 Jan 1;23(1):129-35
pubmed: 16393290
J Gastroenterol Hepatol. 2014 May;29(5):1043-8
pubmed: 24863186
Cancer. 2005 Nov 1;104(9):1948-55
pubmed: 16196045
Br J Surg. 2016 Oct;103(11):1513-20
pubmed: 27550624
Int J Clin Exp Med. 2015 Nov 15;8(11):20581-8
pubmed: 26884976
Cancer Manag Res. 2017 Oct 19;9:525-537
pubmed: 29089785
Medicine (Baltimore). 2017 Mar;96(10):e6246
pubmed: 28272222
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Am J Surg. 2001 Apr;181(4):347-53
pubmed: 11438270
J Surg Oncol. 2011 Sep 1;104(3):292-8
pubmed: 21465490
Ann Surg. 2000 Jul;232(1):10-24
pubmed: 10862190
Am J Surg. 2009 Nov;198(5):693-701
pubmed: 19268907
Asian Pac J Cancer Prev. 2014;15(17):7069-77
pubmed: 25227793